Saturday 17 October 2026
Export BBIO’s income statement to Excel — free account
BridgeBio Pharma, Inc.
BBIO Healthcare Biotechnology
BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024. In the quarter to June 2026, revenue grew 120.4%, EPS grew 17.9%, free cash flow grew 16.6% and total debt rose 4.22%, each against the same quarter a year earlier.
66.39
0.74
−1.10%
Follow BBIO
BridgeBio Pharma, Inc. (BBIO) P/E ratio
BridgeBio Pharma, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 22 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BBIO BridgeBio Pharma, Inc. | n/m |
| SMMT Summit Therapeutics PLC compare | n/m |
| JAZZ Jazz Pharmaceuticals PLC compare | 13.8× |
| ASND Ascendis Pharma A/S compare | 16.3× |
| EXEL Exelixis, Inc. compare | 18.8× |
| HALO Halozyme Therapeutics, Inc. compare | 34.6× |
| TECH Bio-Techne Corp compare | 62.0× |
| BMRN BioMarin Pharmaceutical Inc. compare | 144× |
| CORT Corcept Therapeutics Incorporated compare | 212× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)